These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8176640)

  • 21. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of SHIV for testing HIV-1 vaccine candidates in macaques.
    Lu Y; Salvato MS; Pauza CD; Li J; Sodroski J; Manson K; Wyand M; Letvin N; Jenkins S; Touzjian N; Chutkowski C; Kushner N; LeFaile M; Payne LG; Roberts B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):99-106. PubMed ID: 8680896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.
    Koopman G; Bogers WM; van Gils M; Koornstra W; Barnett S; Morein B; Lehner T; Heeney JL
    J Med Virol; 2007 May; 79(5):474-82. PubMed ID: 17385685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
    Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
    AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
    Lewis MG; Elkins WR; McCutchan FE; Benveniste RE; Lai CY; Montefiori DC; Burke DS; Eddy GA; Shafferman A
    Vaccine; 1993 Oct; 11(13):1347-55. PubMed ID: 7507625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems.
    Sjölander S; Hansen JE; Lövgren-Bengtsson K; Akerblom L; Morein B
    Vaccine; 1996 Mar; 14(4):344-52. PubMed ID: 8744563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection.
    Putkonen P; Thorstensson R; Albert J; Hild K; Norrby E; Biberfeld P; Biberfeld G
    AIDS; 1990 Aug; 4(8):783-9. PubMed ID: 1979745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
    Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120).
    Pyle SW; Morein B; Bess JW; Akerblom L; Nara PL; Nigida SM; Lerche NW; Robey WG; Fischinger PJ; Arthur LO
    Vaccine; 1989 Oct; 7(5):465-73. PubMed ID: 2554608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.
    Quesada-Rolander M; Mäkitalo B; Thorstensson R; Zhang YJ; Castaños-Velez E; Biberfeld G; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):993-9. PubMed ID: 8827215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of HIV-2 and SIVSM infection in cynomolgus monkeys by active or passive immunization.
    Biberfield G; Putkonen P; Thorstensson R; Norrby E
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1511-3. PubMed ID: 1466992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus.
    Berglund P; Quesada-Rolander M; Putkonen P; Biberfeld G; Thorstensson R; Liljeström P
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1487-95. PubMed ID: 9390747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.